The system for which drugs are made available on the NHS in Scotland is different from that of England.
The Scottish NHS seeks guidance from the Scottish Medicines Consortium (SMC) rather than NICE. Everolimus has not yet been submitted by the holder of the marketing authorisation for consideration for this use in Scotland. The SMC are therefore unable to recommend its use at present.
I understand that the procedures that new drugs have to pass through can often seem complex and frustrating. But these processes exist to ensure that the NHS provides the best possible treatment to all patients.